Provided by Tiger Trade Technology Pte. Ltd.

Sol-Gel Technologies

41.15
-0.9750-2.31%
Volume:13.61K
Turnover:549.89K
Market Cap:114.64M
PE:-12.76
High:43.00
Open:43.00
Low:39.26
Close:42.13
52wk High:52.26
52wk Low:4.02
Shares:2.79M
Float Shares:689.35K
Volume Ratio:1.20
T/O Rate:1.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2257
EPS(LYR):-3.7979
ROE:-29.59%
ROA:-16.48%
PB:4.40
PE(LYR):-10.83

Loading ...

Company Profile

Company Name:
Sol-Gel Technologies
Exchange:
NASDAQ
Establishment Date:
1997
Employees:
34
Office Location:
7 Golda Meir Street,Weizmann Science Park,Ness Ziona,Israel
Zip Code:
7403650
Fax:
- -
Introduction:
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Directors

Name
Position
Alon Seri Levy
Chief Executive Officer and Director
Moshe Arkin
Chairman of the Board
Jerrold S. Gattegno
External Director
Ran Gottfried
External Director
Hani Lerman
Director
Itai Arkin
Director
Jonathan B. Siegel
Director
Shmuel Ben Zvi
Director
Yaffa Krindel Sieradzki
Director

Shareholders

Name
Position
Alon Seri Levy
Chief Executive Officer and Director
Gilad Mamlok
Chief Financial Officer
Dov Zamir
Vice President Special Projects
Itzik Yosef
Vice President Operations
John Vieira
U.S. Head of Commercialization
Karine Neimann
Vice President Projects and Planning, Chief Chemist
Nissim Bilman
Vice President Quality
Ofer Toledano
Vice President Research and Development
Ofra Levy Hacham
Vice President Clinical and Regulatory Affairs